Madrigal, FDA approval in hand, outlines plan to sell MASH drug
Bio Pharma Dive
MARCH 15, 2024
The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.
Let's personalize your content